Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

arXiv:2309.03919 · IEEE International Conference on Quantum Computing and Engineering (QCE)

A Hybrid Quantum-classical Fusion Neural Network to Improve Protein-ligand Binding Affinity Predictions for Drug Discovery

Laia Domingo, Mahdi M. Chehimi, S. Banerjee, S. He Yuxun, Subrahmanyam Konakanchi, Lawal Adewale Ogunfowora, Sumantra Dutta Roy, S. Selvarajan, M. Djukic, C. Johnson

Published Sep 15, 2024• 23 citations
arXivHTMLPDF

Abstract

Drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins that influence disease progression, which is financially and computationally demanding. Although classical and hybrid quantum machine learning models have been employed in previous studies to aid in binding affinity prediction, they encounter several issues related to convergence stability and prediction accuracy. In this regard, this paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum circuit architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches. Moreover, to scalably deploy the proposed framework over today's noisy intermediate-scale quantum (NISQ) devices, a novel quantum error mitigation algorithm is proposed. This algorithm outperforms existing techniques and is capable of mitigating errors with gate noise probabilities,$p \leq 0.05$, while resulting in no additional overhead during the training and testing phases.

DOI
10.1109/qce60285.2024.10265

Related papers

Hybrid Quantum Neural Network Approaches to Protein–Ligand Binding Affinity Prediction

Maria Avramouli, Ilias Κ. Savvas, Anna Vasilaki +2 more

Drug repositioning is a less expensive and time-consuming method than the traditional method of drug discovery. It is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. A key strategy in repositioning approved or investigational drugs is determining the binding affinity of these drugs to target proteins. The large increase in available experimental data has helped deep learning methods to demonstrate superior performance compared to conventional prediction and other traditional computational methods in precise binding affinity prediction. However, these methods are complex and time-consuming, presenting a significant barrier to their development and practical application. In this context, quantum computing (QC) and quantum machine learning (QML) theoretically offer promising solutions to effectively address these challenges. In this work, we introduce a hybrid quantum–classical framework to predict binding affinity. Our approach involves, initially, the implementation of an efficient classical model using convolutional neural networks (CNNs) for feature extraction and three fully connected layers for prediction. Subsequently, retaining the classical module for feature extraction, we implement various quantum and classical modules for binding affinity prediction, which accept the concatenated features as input. Quantum predicted modules are implemented with Variational Quantum Regressions (VQRs), while classical predicted modules are implemented with various fully connected layers. Our findings clearly show that hybrid quantum–classical models accelerate the training process in terms of epochs and achieve faster stabilization. Also, these models demonstrate quantum superiority in terms of complexity, accuracy, and generalization, thereby indicating a promising direction for QML.

Mathematics•Jul 30, 2024•15 citations

Hybrid quantum neural networks for efficient protein-ligand binding affinity prediction

Seon-Geun Jeong, Kyeong-Hwan Moon, Won–Joo Hwang

Protein-ligand binding affinity is critical in drug discovery, but experimentally determining it is time-consuming and expensive. Artificial intelligence (AI) has been used to predict binding affinity, significantly accelerating this process. However, the high-performance requirements and vast datasets involved in affinity prediction demand increasingly large AI models, requiring substantial computational resources and training time. Quantum machine learning has emerged as a promising solution to these challenges. In particular, hybrid quantum-classical models can reduce the number of parameters while maintaining or improving performance compared to classical counterparts. Despite these advantages, challenges persist: why hybrid quantum models achieve these benefits, whether quantum neural networks (QNNs) can replace classical neural networks, and whether such models are feasible on noisy intermediate-scale quantum (NISQ) devices. This study addresses these challenges by proposing a hybrid quantum neural network (HQNN) that empirically demonstrates the capability to approximate non-linear functions in the latent feature space derived from classical embedding. The primary goal of this study is to achieve a parameter-efficient model in binding affinity prediction while ensuring feasibility on NISQ devices. Numerical results indicate that HQNN achieves comparable or superior performance and parameter efficiency compared to classical neural networks, underscoring its potential as a viable replacement. This study highlights the potential of hybrid QML in computational drug discovery, offering insights into its applicability and advantages in addressing the computational challenges of protein-ligand binding affinity prediction.

arXiv:2509.11046•EPJ Quantum Technology•Oct 22, 2025•5 citations

An Uncertainty-Aware Adaptive Hybrid Quantum-Classical Learning Framework for Drug Discovery

A. Santhosh Nantha, M. Jayalakshmi, K. Maharajan +2 more

Quantum machine learning (QML) has attracted significant interest in drug discovery due to its potential to model complex molecular interactions and improve prediction accuracy for protein-ligand binding affinity. However, most existing hybrid quantum-classical approaches rely on static architectures that apply quantum computation uniformly across all samples, regardless of molecular complexity or prediction confidence. Such static execution strategies lead to inefficient quantum resource utilization and limit scalability on near-term noisy intermediatescale quantum (NISQ) devices. In this paper, we propose an uncertainty-aware adaptive hybrid quantum-classical learning framework for protein-ligand binding affinity prediction that treats quantum computation as a selectively invoked resource rather than a constant component of the learning pipeline. The proposed framework first employs a classical ensemble-based regression model to generate binding affinity predictions along with an associated uncertainty estimate derived from ensemble variance. This uncertainty information is then used by a decision mechanism to dynamically select between classical-only inference, shallow quantum circuit execution, or deep quantum circuit execution. By adapting the quantum circuit depth and invocation frequency to the predicted uncertainty, the framework enables decision-centric allocation of quantum resources. Experimental evaluation of binding affinity data demonstrates that the recommended adaptive framework utilizes around 76 % less quantum resources than static hybrid quantum learning methods that use fixed-depth quantum circuits for all samples. The framework also preserves decision-level functionality and a steady inference workflow. These findings highlight the effectiveness of uncertainty-guided adaptivity as a practical strategy and offer a scalable foundation for future quantum-enhanced molecular learning.method for incorporating QML into drug development pipelines while taking hardware constraints into consideration.

International Conference on Signal, Systems, and Computing for Next-Gen Automation (ICSSCNA)•May 4, 2026•0 citations

Binding affinity predictions with hybrid quantum-classical convolutional neural networks

Laia Domingo, M. Djukic, C. Johnson +1 more

Central in drug design is the identification of biomolecules that uniquely and robustly bind to a target protein, while minimizing their interactions with others. Accordingly, precise binding affinity prediction, enabling the accurate selection of suitable candidates from an extensive pool of potential compounds, can greatly reduce the expenses associated to practical experimental protocols. In this respect, recent advances revealed that deep learning methods show superior performance compared to other traditional computational methods, especially with the advent of large datasets. These methods, however, are complex and very time-intensive, thus representing an important clear bottleneck for their development and practical application. In this context, the emerging realm of quantum machine learning holds promise for enhancing numerous classical machine learning algorithms. In this work, we take one step forward and present a hybrid quantum-classical convolutional neural network, which is able to reduce by 20% the complexity of the classical counterpart while still maintaining optimal performance in the predictions. Additionally, this results in a significant cost and time savings of up to 40% in the training stage, which means a substantial speed-up of the drug design process.

arXiv:2301.06331•Scientific Reports•Oct 20, 2023•45 citations

Hybrid VQE–Graph Neural Network Framework for Scalable Binding-Affinity Prediction

Neeraja P, J Umamageswaran

The Variational Quantum Eigensolver (VQE) has emerged as a viable method for calculating molecular energies through its combination of quantum and classical computing power on NISQ systems. The existing methods for predicting binding affinities in intricate systems face difficulties because of two major problems which are noise issues and the inability to handle large systems. The Hybrid VQE-Graph Neural Network (VQE-GNN) solution which we present enables us to achieve accurate binding affinity predictions by using quantum molecular feature learning together with graph neural network technology. Our method combines Hamiltonian Fragmentation with a noise-resilient VQE approach and an attention-steered Graph Neural Network. The research project aims to create a solution which combines precise quantum chemistry results with practical machine learning models. The experiments which researchers conducted on both the PDBbind and BindingDB datasets demonstrated that our approach accomplished better prediction results together with improved correlation and ligand ranking performance when compared to standard GNNs which proves that quantum-classical hybrid systems hold considerable promise for drug discovery research.

International Conference on Computational Robotics, Testing and Engineering Evaluation (ICCRTEE)•May 14, 2026•0 citations

Quantum–Classical Neural Networks with Variational Circuits for Molecular Docking in Drug Discovery

K. Kalaiselvi, G. Husna Khouser, Kavitha A K +3 more

This work aims to propose a Quantum-Classical Neural Network with Variational quantum circuit (QCNN-VQC) to improve the accuracy of molecular docking in drug discovery. The model combines the classical feature extraction framework with quantum representations and energy-based optimisation to simulate intricate protein-ligand interactions. The molecular features are initially encoded into quantum states by first a standard neural network and then by encoding them into quantum states, where non-linear correlations and entanglement effects are modeled by variational circuits. An optimization strategy is used, that is quantum-inspired to achieve the minimum docking energy and find stable binding conformations. The experimental analysis of molecular docking datasets reveals that the proposed model achieves an accuracy of 91.2% compared to the classical neural networks (78.5%), and deep learning models (82.3%). The model also has a lower RMSE of 0.38 and higher R2score of 0.89 which means that it predicts better. The results of energy minimization indicate that the docking energy is greatly reduced, which proves the increased binding stability. The hybrid model is slightly more expensive to compute but it has competitive inference time. In general, QCNN VQC architecture offers a scalable and efficient drug discovery system; it can be optimally applied to quantum optimization in conjunction with deep learning and can result in a better prediction and strong molecular interaction modeling.

International Conference on Cognitive Computing and Networking Systems (ICC-CNS)•Jun 1, 2026•0 citations
Drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins that influence disease progression, which is financially and computationally demanding. Although classical and hybrid quantum machine learning models have been employed in previous studies to aid in binding affinity prediction, they encounter several issues related to convergence stability and prediction accuracy. In this regard, this paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum circuit architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches. Moreover, to scalably deploy the proposed framework over today's noisy intermediate-scale quantum (NISQ) devices, a novel quantum error mitigation algorithm is proposed. This algorithm outperforms existing techniques and is capable of mitigating errors with gate noise probabilities,p≤0.05p \leq 0.05p≤0.05, while resulting in no additional overhead during the training and testing phases.
Drug repositioning is a less expensive and time-consuming method than the traditional method of drug discovery. It is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. A key strategy in repositioning approved or investigational drugs is determining the binding affinity of these drugs to target proteins. The large increase in available experimental data has helped deep learning methods to demonstrate superior performance compared to conventional prediction and other traditional computational methods in precise binding affinity prediction. However, these methods are complex and time-consuming, presenting a significant barrier to their development and practical application. In this context, quantum computing (QC) and quantum machine learning (QML) theoretically offer promising solutions to effectively address these challenges. In this work, we introduce a hybrid quantum–classical framework to predict binding affinity. Our approach involves, initially, the implementation of an efficient classical model using convolutional neural networks (CNNs) for feature extraction and three fully connected layers for prediction. Subsequently, retaining the classical module for feature extraction, we implement various quantum and classical modules for binding affinity prediction, which accept the concatenated features as input. Quantum predicted modules are implemented with Variational Quantum Regressions (VQRs), while classical predicted modules are implemented with various fully connected layers. Our findings clearly show that hybrid quantum–classical models accelerate the training process in terms of epochs and achieve faster stabilization. Also, these models demonstrate quantum superiority in terms of complexity, accuracy, and generalization, thereby indicating a promising direction for QML.
Protein-ligand binding affinity is critical in drug discovery, but experimentally determining it is time-consuming and expensive. Artificial intelligence (AI) has been used to predict binding affinity, significantly accelerating this process. However, the high-performance requirements and vast datasets involved in affinity prediction demand increasingly large AI models, requiring substantial computational resources and training time. Quantum machine learning has emerged as a promising solution to these challenges. In particular, hybrid quantum-classical models can reduce the number of parameters while maintaining or improving performance compared to classical counterparts. Despite these advantages, challenges persist: why hybrid quantum models achieve these benefits, whether quantum neural networks (QNNs) can replace classical neural networks, and whether such models are feasible on noisy intermediate-scale quantum (NISQ) devices. This study addresses these challenges by proposing a hybrid quantum neural network (HQNN) that empirically demonstrates the capability to approximate non-linear functions in the latent feature space derived from classical embedding. The primary goal of this study is to achieve a parameter-efficient model in binding affinity prediction while ensuring feasibility on NISQ devices. Numerical results indicate that HQNN achieves comparable or superior performance and parameter efficiency compared to classical neural networks, underscoring its potential as a viable replacement. This study highlights the potential of hybrid QML in computational drug discovery, offering insights into its applicability and advantages in addressing the computational challenges of protein-ligand binding affinity prediction.
Quantum machine learning (QML) has attracted significant interest in drug discovery due to its potential to model complex molecular interactions and improve prediction accuracy for protein-ligand binding affinity. However, most existing hybrid quantum-classical approaches rely on static architectures that apply quantum computation uniformly across all samples, regardless of molecular complexity or prediction confidence. Such static execution strategies lead to inefficient quantum resource utilization and limit scalability on near-term noisy intermediatescale quantum (NISQ) devices. In this paper, we propose an uncertainty-aware adaptive hybrid quantum-classical learning framework for protein-ligand binding affinity prediction that treats quantum computation as a selectively invoked resource rather than a constant component of the learning pipeline. The proposed framework first employs a classical ensemble-based regression model to generate binding affinity predictions along with an associated uncertainty estimate derived from ensemble variance. This uncertainty information is then used by a decision mechanism to dynamically select between classical-only inference, shallow quantum circuit execution, or deep quantum circuit execution. By adapting the quantum circuit depth and invocation frequency to the predicted uncertainty, the framework enables decision-centric allocation of quantum resources. Experimental evaluation of binding affinity data demonstrates that the recommended adaptive framework utilizes around 76 % less quantum resources than static hybrid quantum learning methods that use fixed-depth quantum circuits for all samples. The framework also preserves decision-level functionality and a steady inference workflow. These findings highlight the effectiveness of uncertainty-guided adaptivity as a practical strategy and offer a scalable foundation for future quantum-enhanced molecular learning.method for incorporating QML into drug development pipelines while taking hardware constraints into consideration.
Central in drug design is the identification of biomolecules that uniquely and robustly bind to a target protein, while minimizing their interactions with others. Accordingly, precise binding affinity prediction, enabling the accurate selection of suitable candidates from an extensive pool of potential compounds, can greatly reduce the expenses associated to practical experimental protocols. In this respect, recent advances revealed that deep learning methods show superior performance compared to other traditional computational methods, especially with the advent of large datasets. These methods, however, are complex and very time-intensive, thus representing an important clear bottleneck for their development and practical application. In this context, the emerging realm of quantum machine learning holds promise for enhancing numerous classical machine learning algorithms. In this work, we take one step forward and present a hybrid quantum-classical convolutional neural network, which is able to reduce by 20% the complexity of the classical counterpart while still maintaining optimal performance in the predictions. Additionally, this results in a significant cost and time savings of up to 40% in the training stage, which means a substantial speed-up of the drug design process.
The Variational Quantum Eigensolver (VQE) has emerged as a viable method for calculating molecular energies through its combination of quantum and classical computing power on NISQ systems. The existing methods for predicting binding affinities in intricate systems face difficulties because of two major problems which are noise issues and the inability to handle large systems. The Hybrid VQE-Graph Neural Network (VQE-GNN) solution which we present enables us to achieve accurate binding affinity predictions by using quantum molecular feature learning together with graph neural network technology. Our method combines Hamiltonian Fragmentation with a noise-resilient VQE approach and an attention-steered Graph Neural Network. The research project aims to create a solution which combines precise quantum chemistry results with practical machine learning models. The experiments which researchers conducted on both the PDBbind and BindingDB datasets demonstrated that our approach accomplished better prediction results together with improved correlation and ligand ranking performance when compared to standard GNNs which proves that quantum-classical hybrid systems hold considerable promise for drug discovery research.
This work aims to propose a Quantum-Classical Neural Network with Variational quantum circuit (QCNN-VQC) to improve the accuracy of molecular docking in drug discovery. The model combines the classical feature extraction framework with quantum representations and energy-based optimisation to simulate intricate protein-ligand interactions. The molecular features are initially encoded into quantum states by first a standard neural network and then by encoding them into quantum states, where non-linear correlations and entanglement effects are modeled by variational circuits. An optimization strategy is used, that is quantum-inspired to achieve the minimum docking energy and find stable binding conformations. The experimental analysis of molecular docking datasets reveals that the proposed model achieves an accuracy of 91.2% compared to the classical neural networks (78.5%), and deep learning models (82.3%). The model also has a lower RMSE of 0.38 and higher R2score of 0.89 which means that it predicts better. The results of energy minimization indicate that the docking energy is greatly reduced, which proves the increased binding stability. The hybrid model is slightly more expensive to compute but it has competitive inference time. In general, QCNN VQC architecture offers a scalable and efficient drug discovery system; it can be optimally applied to quantum optimization in conjunction with deep learning and can result in a better prediction and strong molecular interaction modeling.